A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women

By Alejandro Rabinstein. 2006

1,305 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/541bbf416712afab73ff5a2e0a3d7db80ba4cb19

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. P. Ridker
2. N. Rifai
3. Nancy R. Cook
4. C. Herrmann-Lingen
5. S. Laurent
6. I. Graham
7. R. Dana
8. R. Redberg

In Surgery

1. P. Ridker
2. N. Rifai
3. I. Graham
4. R. Dana
5. R. Redberg
6. D. Sullivan
7. C. Bushnell
8. Nancy R. Cook

Citations in the corpus

• European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invit (2007, positive): “In heart failure patients or those with left ventricular dysfunction, ACE inhibitors have been shown to reduce risk of death, recurrent MI, and progression to persistent heart failure.227 ACE inhibitor treatment also reduced risk of death after AMI.”
• 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2007, result): “These observations are in line with those of several meta-analyses of primary prevention studies, also including non-hypertensive patients, and with the recent results of the Women Prevention Study in a large cohort of very low risk subjects, showing little net benefit of aspirin.(766) Therefore, tr”
• Cardiovascular disease in women (2010, positive): “Overall, the trial showed a statistically nonsignificant 9% reduction in the primary composite outcome of major CVD events with low-dose ASA.(125) ASA significantly lowered the risk of total stroke by 17% (CI, 0.”
• Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. (2016, background): “ports that aspirin protects more against stroke in women and more against MI in men.(149) The reason is unclear.”
• Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. (2005, methodology): “In this regard, there was virtually no use of statin therapy at the time of enrollment into the WHS and overall usage rates remained very low at all points of follow-up reflecting the low-risk nature of this cohort.(19) However, in the Air Force Texas Coronary Atherosclerosis Prevention Study (AFCAP”
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials (2006, neutral): “Hypertension 1986 (9) 514 (10) 1322 (26) 9907 (100) 8883 (100) 1285 (67) 1780 (69) 10 328 (26)”